Amarin Corporation plc (AMRN)
NASDAQ$0.4138
Market Cap
$170.18M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
291 of 924
Rank in Industry
167 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
AMRN Insider Trading Activity
AMRN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $102,400 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Berg Aaron | President and CEO | 1 | $102,400 | 0 | $0 | $102,400 |
About Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with …
Insider Activity of Amarin Corporation plc
Over the last 12 months, insiders at Amarin Corporation plc have bought $102,400 and sold $0 worth of Amarin Corporation plc stock.
On average, over the past 5 years, insiders at Amarin Corporation plc have bought $174,734 and sold $5.19M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Berg Aaron (President and CEO) — $102,400.
The last purchase of 160,000 shares for transaction amount of $102,400 was made by Berg Aaron (President and CEO) on 2024‑08‑02.
List of Insider Buy and Sell Transactions, Amarin Corporation plc
| 2024-08-02 | Berg Aaron | President and CEO | 160,000 0.0389% | $0.64 | $102,400 | -10.08% | ||
| 2024-01-22 | Holt Patrick | President and CEO | 14,426 0.0033% | $1.09 | $15,724 | -39.29% | ||
| 2023-12-12 | Sale | Ketchum Steven B | Chief Scientific Officer | 34,131 0.0084% | $0.79 | $26,963 | -0.54% | |
| 2023-08-16 | Holt Patrick | President and CEO | 300,000 0.0723% | $1.04 | $312,315 | -18.77% | ||
| 2022-06-13 | WOLD OLSEN PER | 55,000 0.0137% | $1.69 | $92,730 | -21.76% | |||
| 2021-12-15 | Zakrzewski Joseph S | director | 2,000 0.0005% | $3.15 | $6,310 | -52.31% | ||
| 2021-12-14 | Zakrzewski Joseph S | director | 10,000 0.0025% | $3.27 | $32,689 | -52.00% | ||
| 2021-08-12 | Sale | Kalb Michael Wayne | SVP and CFO | 120,000 0.0282% | $5.25 | $630,240 | -41.05% | |
| 2021-06-04 | STACK DAVID M | director | 10,000 0.0026% | $4.54 | $45,350 | -17.42% | ||
| 2021-06-03 | STACK DAVID M | director | 5,000 0.0013% | $4.62 | $23,115 | -19.61% | ||
| 2021-02-01 | Sale | Ketchum Steven B | Chief Scientific Officer | 435,456 0.11% | $8.06 | $3.51M | -39.85% | |
| 2021-01-27 | Sale | Ketchum Steven B | Chief Scientific Officer | 843,258 0.2332% | $8.01 | $6.76M | -33.52% | |
| 2020-11-30 | STACK DAVID M | director | 50,000 0.0125% | $4.86 | $243,035 | +1.61% | ||
| 2020-11-11 | Sale | THERO JOHN F | President and CEO | 827,130 0.2094% | $4.07 | $3.36M | +22.63% | |
| 2020-11-10 | Sale | THERO JOHN F | President and CEO | 307,680 0.0792% | $4.13 | $1.27M | +22.63% | |
| 2020-03-04 | Sale | THERO JOHN F | President and CEO | 400,000 0.1106% | $15.99 | $6.4M | -58.77% | |
| 2020-01-03 | Sale | Zakrzewski Joseph S | director | 600,000 0.0965% | $12.17 | $7.3M | -67.88% | |
| 2019-12-16 | Sale | Berg Aaron | CHIEF COMMERCIAL OFFICER | 86,506 0.02% | $19.03 | $1.65M | -70.15% | |
| 2019-12-16 | Sale | Zakrzewski Joseph S | director | 200,000 0.0424% | $17.42 | $3.48M | -70.15% | |
| 2019-12-16 | Sale | Kalb Michael Wayne | SVP and CFO | 50,000 0.0142% | $23.36 | $1.17M | -70.15% |
Total: 191
*Gray background shows transactions not older than one year
Insider Historical Profitability
15.45%
| Berg Aaron | President and CEO | 805380 0.1958% | $333,266.24 | 1 | 4 | |
| THERO JOHN F | President and CEO | 2739000 0.666% | $1.13M | 6 | 9 | +65.82% |
| Holt Patrick | President and CEO | 314426 0.0765% | $130,109.48 | 2 | 0 | <0.0001% |
| Zakrzewski Joseph S | director | 196547 0.0478% | $81,331.15 | 3 | 16 | <0.0001% |
| WOLD OLSEN PER | 149000 0.0362% | $61,656.20 | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$2,924,567 | 72 | -4.87% | $157.74M | |
$613,304,943 | 46 | 11.85% | $191.55M | |
$48,218,096 | 42 | 0.89% | $204.72M | |
$79,019,806 | 27 | 7.24% | $165.26M | |
$6,915,275 | 21 | -32.61% | $158.47M |
AMRN Institutional Investors: Active Positions
| Increased Positions | 55 | +26.57% | 10M | +15.69% |
| Decreased Positions | 72 | -34.78% | 4M | -6.46% |
| New Positions | 27 | New | 4M | New |
| Sold Out Positions | 23 | Sold Out | 388,145 | Sold Out |
| Total Postitions | 190 | -8.21% | 72M | +9.23% |
AMRN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Sarissa Capital Management Lp | $13,469.00 | 6.05% | 24.85M | 0 | 0% | 2024-12-31 |
| Kynam Capital Management, Lp | $6,729.00 | 3.02% | 12.41M | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $2,388.00 | 1.07% | 4.41M | +2M | +73.09% | 2024-12-31 |
| Scp Investment, Lp | $1,355.00 | 0.61% | 2.5M | 0 | 0% | 2024-12-31 |
| Waterfront Wealth Inc. | $1,345.00 | 0.6% | 2.48M | +2M | +181.44% | 2024-12-31 |
| Two Sigma Investments, Lp | $1,178.00 | 0.53% | 2.17M | -206,279 | -8.67% | 2024-12-31 |
| Acadian Asset Management Llc | $968.00 | 0.44% | 1.79M | +2M | +578.97% | 2024-12-31 |
| Two Sigma Advisers, Lp | $943.00 | 0.42% | 1.74M | -236,700 | -11.98% | 2024-12-31 |
| Longitude (Cayman) Ltd. | $878.00 | 0.39% | 1.62M | -750,000 | -31.65% | 2024-12-31 |
| Eversept Partners, Lp | $822.00 | 0.37% | 1.52M | -2M | -54.17% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.